1. Home
  2. FRAF vs EYPT Comparison

FRAF vs EYPT Comparison

Compare FRAF & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Financial Services Corporation

FRAF

Franklin Financial Services Corporation

BUY

Current Price

$63.95

Market Cap

279.0M

Sector

Finance

ML Signal

BUY

EYPT

EyePoint Pharmaceuticals Inc.

BUY

Current Price

$3.45

Market Cap

273.3M

Sector

Industrials

ML Signal

BUY

Company Overview

Basic Information
Metric
FRAF
EYPT
Founded
1906
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
279.0M
273.3M
IPO Year
1995
2005

Fundamental Metrics

Financial Performance
Metric
FRAF
EYPT
Price
$63.95
$3.45
Analyst Decision
Buy
Analyst Count
0
13
Target Price
N/A
★ $25.91
AVG Volume (30 Days)
25.4K
★ 3.2M
Earning Date
10-27-2026
11-04-2026
Dividend Yield
★ 2.15%
N/A
EPS Growth
★ 88.84
N/A
EPS
★ 2.94
N/A
Revenue
N/A
★ $7,539,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.58
$967.16
P/E Ratio
$21.54
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$43.47
$3.05
52 Week High
$65.41
$19.11

Technical Indicators

Market Signals
Indicator
FRAF
EYPT
Relative Strength Index (RSI) 53.99 34.18
Support Level $60.34 N/A
Resistance Level $64.44 $14.72
Average True Range (ATR) 1.58 0.26
MACD 0.08 0.18
Stochastic Oscillator 81.28 31.33

Price Performance

Historical Comparison
FRAF
EYPT

About FRAF Franklin Financial Services Corporation

Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Share on Social Networks: